Felipe C. Ribeiro

Felipe C. Ribeiro

Auto-generated profile, based on publicly available information

Felipe C. Ribeiro

Institute of Medical Biochemistry Leopoldo de Meis Federal University of Rio de Janeiro Rio de Janeiro Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JCJulia R Clarke
Julia R Clarke
NSNatalia M Lyra e Silva
Natalia M Lyra e Silva
CFClaudia pinto Figueiredo
Claudia pinto Figueiredo
RFRudimar Frozza
Rudimar Frozza
JLJose H Ledo
Jose H Ledo
FFFernanda G De Felice
Fernanda G De Felice
Alzheimer's disease (AD) is associated with peripheral metabolic disorders. Clinical/epidemiological data indicate increased risk of diabetes in AD patients. Here, we show that intracerebroventricular infusion of AD‐associated Aβ oligomers (AβOs) in mice triggered peripheral glucose intolerance, a phenomenon further verified in two transgenic mouse models of AD. Systemically injected AβOs failed to induce glucose intolerance, suggesting AβOs target brain regions involved in peripheral metabolic control. Accordingly, we show that AβOs affected hypothalamic neurons in culture, inducing eukaryotic translation initiation factor 2α phosphorylation (eIF2α‐P). AβOs further induced eIF2α‐P and activated pro‐inflammatory IKKβ/NF‐κB signaling in the hypothalamus of mice and macaques. AβOs failed to trigger peripheral glucose intolerance in tumor necrosis factor‐α (TNF‐α) receptor 1 knockout mice. Pharmacological inhibition of brain inflammation and endoplasmic reticulum stress prevented glucose intolerance in mice, indicating that AβOs act via a central route to affect peripheral glucose homeostasis. While the hypothalamus has been largely ignored in the AD field, our findings indicate that AβOs affect this brain region and reveal novel shared molecular mechanisms between hypothalamic dysfunction in metabolic disorders and AD.

5 June 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
CFClaudia pinto Figueiredo
Claudia pinto Figueiredo
JCJulia R. Clarke
Julia R. Clarke
JLJosé Henrique Ledo
José Henrique Ledo
FRFelipe C. Ribeiro
Felipe C. Ribeiro
CCCarine V. Costa
Carine V. Costa
SFSergio T. Ferreira
Sergio T. Ferreira
Brain accumulation of soluble amyloid-β oligomers (AβOs) has been implicated in synapse failure and cognitive impairment in Alzheimer's disease (AD). However, whether and how oligomers of different sizes induce synapse dysfunction is a matter of controversy. Here, we report that low-molecular-weight (LMW) and high-molecular-weight (HMW) Aβ oligomers differentially impact synapses and memory. A single intracerebroventricular injection of LMW AβOs (10 pmol) induced rapid and persistent cognitive impairment in mice. On the other hand, memory deficit induced by HMW AβOs (10 pmol) was found to be reversible. While memory impairment in LMW oligomer-injected mice was associated with decreased hippocampal synaptophysin and GluN2B immunoreactivities, synaptic pathology was not detected in the hippocampi of HMW oligomer-injected mice. On the other hand, HMW oligomers, but not LMW oligomers, induced oxidative stress in hippocampal neurons. Memantine rescued both neuronal oxidative stress and the transient memory impairment caused by HMW oligomers, but did not prevent the persistent cognitive deficit induced by LMW oligomers. Results establish that different Aβ oligomer assemblies act in an orchestrated manner, inducing different pathologies and leading to synapse dysfunction. Furthermore, results suggest a mechanistic explanation for the limited efficacy of memantine in preventing memory loss in AD.

27 November 2012 in Molecular Psychiatry
Verified
Journal Article
Open access
JLJ H Ledo
J H Ledo
EAE P Azevedo
E P Azevedo
JCJ R Clarke
J R Clarke
FRF C Ribeiro
F C Ribeiro
CFClaudia pinto Figueiredo
Claudia pinto Figueiredo
SFS T Ferreira
S T Ferreira
Molecular Psychiatry publishes work aimed at elucidating biological mechanisms underlying psychiatric disorders and their treatment

30 November 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JLJose Henrique Ledo
Jose Henrique Ledo
EAEstefania P. Azevedo
Estefania P. Azevedo
DBDanielle Beckman
Danielle Beckman
FRFelipe C. Ribeiro
Felipe C. Ribeiro
LSLuis E. Santos
Luis E. Santos
SFSergio T. Ferreira
Sergio T. Ferreira
Considerable clinical and epidemiological evidence links Alzheimer's disease (AD) and depression. However, the molecular mechanisms underlying this connection are largely unknown. We reported recently that soluble Aβ oligomers (AβOs), toxins that accumulate in AD brains and are thought to instigate synapse damage and memory loss, induce depressive-like behavior in mice. Here, we report that the mechanism underlying this action involves AβO-induced microglial activation, aberrant TNF-α signaling, and decreased brain serotonin levels. Inactivation or ablation of microglia blocked the increase in brain TNF-α and abolished depressive-like behavior induced by AβOs. Significantly, we identified serotonin as a negative regulator of microglial activation. Finally, AβOs failed to induce depressive-like behavior in Toll-like receptor 4-deficient mice and in mice harboring a nonfunctional TLR4 variant in myeloid cells. Results establish that AβOs trigger depressive-like behavior via a double impact on brain serotonin levels and microglial activation, unveiling a cross talk between brain innate immunity and serotonergic signaling as a key player in mood alterations in AD.SIGNIFICANCE STATEMENTAlzheimer's disease (AD) is a progressive neurodegenerative disorder and the main cause of dementia in the world. Brain accumulation of amyloid-β oligomers (AβOs) is a major feature in the pathogenesis of AD. Although clinical and epidemiological data suggest a strong connection between AD and depression, the underlying mechanisms linking these two disorders remain largely unknown. Here, we report that aberrant activation of the brain innate immunity and decreased serotonergic tonus in the brain are key players in AβO-induced depressive-like behavior in mice. Our findings may open up new possibilities for the development of effective therapeutics for AD and depression aimed at modulating microglial function.

21 January 2023 in Ageing Research Reviews
Verified
Journal Article
Closed access
DCDanielle Cozachenco
Danielle Cozachenco
FRFelipe C. Ribeiro
Felipe C. Ribeiro
SFSergio T. Ferreira
Sergio T. Ferreira

1 March 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JBJordano Brito-Moreira
Jordano Brito-Moreira
MLMychael V. Lourenco
Mychael V. Lourenco
MOMauricio M. Oliveira
Mauricio M. Oliveira
FRFelipe C. Ribeiro
Felipe C. Ribeiro
JLJosé Henrique Ledo
José Henrique Ledo
SFSergio T. Ferreira
Sergio T. Ferreira
Brain accumulation of the amyloid-β protein (Aβ) and synapse loss are neuropathological hallmarks of Alzheimer disease (AD). Aβ oligomers (AβOs) are synaptotoxins that build up in the brains of patients and are thought to contribute to memory impairment in AD. Thus, identification of novel synaptic components that are targeted by AβOs may contribute to the elucidation of disease-relevant mechanisms. Trans-synaptic interactions between neurexins (Nrxs) and neuroligins (NLs) are essential for synapse structure, stability, and function, and reduced NL levels have been associated recently with AD. Here we investigated whether the interaction of AβOs with Nrxs or NLs mediates synapse damage and cognitive impairment in AD models. We found that AβOs interact with different isoforms of Nrx and NL, including Nrx2α and NL1. Anti-Nrx2α and anti-NL1 antibodies reduced AβO binding to hippocampal neurons and prevented AβO-induced neuronal oxidative stress and synapse loss. Anti-Nrx2α and anti-NL1 antibodies further blocked memory impairment induced by AβOs in mice. The results indicate that Nrx2α and NL1 are targets of AβOs and that prevention of this interaction reduces the deleterious impact of AβOs on synapses and cognition. Identification of Nrx2α and NL1 as synaptic components that interact with AβOs may pave the way for development of novel approaches aimed at halting synapse failure and cognitive loss in AD.